Background: Targeting low-dose computed tomography (LDCT) for lung cancer screening to persons at highest risk for lung cancer mortality has been suggested to improve screening efficiency.
T
he National Lung Screening Trial (NLST) demonstrated a 20% reduction in lung cancer deaths among persons screened with low-dose computed tomography (LDCT) versus chest radiography (1) . The study participants were between the ages of 55 and 74 years and had a smoking history of at least 30 packyears; former smokers had no more than 15 years of smoking abstinence (1) . Most subsequent guidelines, including those from the U.S. Preventive Services Task Force (USPSTF), have largely adopted the NLST eligibility criteria when recommending who should receive lung cancer screening (2) (3) (4) .
A retrospective analysis of the NLST showed that 60% of participants at highest predicted risk for lung cancer death accounted for 88% of all screeningprevented lung cancer mortality (5) . Other influential studies also have suggested that using several risk factors to selected participants with the highest predicted risk for either having or dying of lung cancer would greatly improve the efficiency and yield of lung cancer screening (6 -10) . A general limitation of these studies is that the benefits of screening with LDCT is measured in terms of reduced lung cancer mortality over the short term, generally the first 5 to 7 years per patient screened; these studies do not account for differences in long-term survival or costs in higher-versus lowerrisk patients.
In this analysis, we applied a novel multistate model to calculate the predicted lifetime benefits and costs of screening with LDCT versus chest radiography for each NLST participant. We used these estimates to examine the value of applying an individualized risktargeted approach to selecting participants for screening compared with the broader NLST inclusion criteria at common willingness-to-pay (WTP) thresholds.
Appendix (available at Annals.org). This technique jointly estimates the baseline hazards and the effects of risk factors on 4 transitions among the 4 health states shown in Figure 1 : alive without cancer, alive with lung cancer, dead as a result of other causes, and dead as a result of lung cancer. The resulting equation provides individualized predictions, under each screening condition, of the probability of being in each of the 4 states at any given time point. These predictions were used to risk stratify the population as well as estimate individualized lung cancer mortality benefits of LDCT screening at 7 years. To estimate individualized lifetime health benefits, extrapolations of the baseline hazards were used to project the probability of being in each of the 4 states beyond 7 years. Individualized costs were estimated by using utilization data from the NLST and linear regression prediction models combined with assumptions to estimate lifetime medical costs. For the purposes of presentation, we stratified participants into deciles (10% cohorts) on the basis of their 7-year risk for lung cancer mortality when screened with chest radiography. Finally, we calculated the incremental net monetary benefit (iNMB) for each participant to summarize the value of a risk-stratified screening strategy compared with the NLST inclusion criteria at common WTP thresholds of $50 000 and $100 000 per qualityadjusted life-year (QALY) (13, 14) .
Model Derivation and Validation
The NLST randomly assigned 53 454 participants to have 3 consecutive annual screenings from randomization (years 0, 1, and 2) with either LDCT (n = 26 722) or the control screening method of chest radiography (n = 26 732). Median follow-up was 6.5 years. Our multistate regression model included 8 baseline variables for each NLST participant (age, sex, race, family history in a first-degree relative, body mass index, smoking exposure [pack-years], years since smoking cessation, and self-reported history of emphysema). We selected these variables on the basis of a previously published model (5) . We excluded 368 NLST participants for whom data were missing for any of these variables. Because the transition from smoker to lung cancer did not satisfy the proportional hazard assumption (as the difference in lung cancer diagnoses between screening conditions occurred mostly within the first year after randomization), participants were stratified on initial screening assignment. The proportional hazards assumption also was checked for all other included variables over each of the 4 transitions by examining the correlation of the Schoenfeld residuals with time. Proportionality in the 7-year follow-up data generally was not rejected, nor was any evidence found of a consistent nonsignificant trend for diminishing or strengthening predictor effects over time.
To evaluate model performance, we constructed calibration plots under each screening condition for the observed proportions of outcome events against the predicted risks for individuals grouped by quintiles (20% cohorts) of risk. We used the concordance statistic (c-statistic) to assess model discrimination. All analyses were performed by using R, version 3.3.2 (The R Foundation), and SAS, version 9.3 (SAS Institute).
Benefits
We estimated benefits for each participant as the incremental model-projected health outcomes after LDCT compared with chest radiography screening. We used the multistate model to project potential outcomes for each subject through year 7 after randomization. We extrapolated subsequent survival conditional on survival to year 7 by using a Weibull distribution ORIGINAL RESEARCH Risk-Targeted Selection for Lung Cancer Screening (Appendix Figure 1 , available at Annals.org). Health outcomes included life expectancy and qualityadjusted life expectancy under each screening condition for each person. We computed the expected QALYs as the sum of each health state's contribution. Each state's contribution was equal to the product of the expected years lived in that state and the state's utility weight. The utility weights used were 1.0 (equivalent to 1 year of perfect health) for the initial state of being alive without lung cancer, 0.77 for alive with lung cancer (the average utility for metastatic and nonmetastatic lung cancer reported in a meta-analysis [15] ), and 0.0 (equivalent to death).
Costs
Cost components included the initial screening; medical care use, including diagnosis and management after a positive screening result; and agestratified background medical costs (Appendix Tables  1 and 2 , available at Annals.org) (14) . We estimated initial screening costs and costs associated with a positive screening as the product of utilization data and unit prices (by using 2016 Medicare reimbursement [16] ). Utilization estimates came directly from the NLST, which recorded diagnostic and procedure codes pertinent to the screening, diagnosis, and treatment of lung cancer for each participant. Our analysis focused on codes that had at least a minimally significant difference between the 2 treatment groups, defined as an absolute difference of at least 10. Our analysis included 35 diagnostic procedures, 13 treatment codes, and 5 complication codes, in addition to costs for screening (Appendix Table 1 ).
These empirically derived incremental costs were used in a generalized linear regression equation, which was based on 9 characteristics (the 8 variables included in the risk model plus treatment group [LDCT vs. chest radiography]), to predict each patient's expected incremental costs (expected cost with LDCT minus expected cost with chest radiography).
Analysis
Cost-effectiveness analyses assessed the comparative value of screening with LDCT versus chest radiography for each participant by using incremental costeffectiveness ratios (ICERs). We calculated the ICER for each patient as the predicted incremental cost of screening with LDCT compared with radiography divided by the predicted incremental benefits of LDCT. All analyses were performed from the perspective of the health care sector, and all future life-years and costs were discounted at 3% (17) .
We calculated the iNMB of a risk-targeted screening strategy compared with the best strategy applied to all participants enrolled in the NLST. The iNMB provides a useful summary of both the health and the economic gains of an intervention by expressing them on the same scale, converting net health benefits into monetary terms (multiplying incremental QALYs by the WTP threshold [18] ). Here, in addition to determining the "conversion rate" for a QALY, the WTP threshold also determines the lung cancer mortality risk threshold at which the more expensive screening technology (LDCT) is deemed cost-effective. Risk targeting improves cost-effectiveness by switching the patients above or below this risk threshold to (or from) LDCT for whom the switch accrues a positive iNMB (that is, the switch is cost-effective at a given WTP threshold). We used the commonly applied WTP thresholds of $50 000 and $100 000 per QALY (13) . The per-patient iNMB is the aggregate gain across all switched patients divided by the number of those screened.
Sensitivity Analyses
We assessed the influence of the following alternative assumptions on the model-projected cost-effectiveness: LDCT provides continually accruing lung cancer mortality gains by extrapolating the reduced hazard of lung cancer mortality throughout the patient's lifetime (Appendix Figure 1) , age-specific background medical costs are removed, and a utility weight of 0.57 or 1.0 is assigned after a lung cancer diagnosis (base case, 0.77) (15) .
This study was approved for exemption by the Tufts Institutional Review Board.
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RESULTS

Multistate Prediction Model and Study Population
Appendix Table 3 (available at Annals.org) summarizes the multistate regression model; risk factors and their associated hazard ratios are shown for lung cancer incidence, lung cancer death, and competing causes of death. Transition-specific discrimination measured by the c-statistic ranged from 0.61 (95% CI, 0.59 to 0.63) for lung cancer to death to 0.70 (CI, 0.68 to 0.72) for progression from the healthy state to a diagnosis of lung cancer. Excellent agreement was found between outcomes predicted by the model (including lung cancer diagnosis, lung cancer mortality, and non-lung cancer mortality) and those observed within the trial period (Appendix Figure 2 , available at Annals.org).
After the 53 086 NLST participants were stratified by their baseline risk for lung cancer mortality, the highest-versus lowest-risk quintile participants, on average, were 8 years older and more likely to be white, be male, have a positive family history of lung cancer, be a current smoker with an exposure of 30 or more pack-years, and have an underlying diagnosis of emphysema ( Table 1) .
Health Benefit
The lung cancer mortality benefit from LDCT (compared with chest radiography) screening increased with increasing baseline risk for death from lung cancer (Figure 2) . For the participants at lowest risk (decile 1), LDCT screening prevented 1.2 deaths from lung cancer per 10 000 person-years, compared with 9.5 deaths from lung cancer per 10 000 person-years for patients at highest risk (decile 10). Benefits also increased across increasing risk deciles when expressed as lifeyears gained (0.015 and 0.056 life-years for deciles 1 and 10, respectively) and QALYs gained (0.011 and 0.028 QALYs in deciles 1 and 10, respectively) ( Figure  2 ). Comparing the benefit gradient across risk groups, the extreme (highest to lowest) decile ratio was greatest in terms of lung cancer mortality benefits in the first 7 years (ratio, 7.9). The extreme decile ratio was greatly attenuated when comparing life-years gained (ratio, 3.6), with further attenuation when comparing QALYs gained (ratio, 2.4) (Figure 2 ).
Costs and Incremental Cost-Effectiveness
Screening with LDCT increased lifetime costs by $1089 versus screening with chest radiography, yielding an ICER for LDCT of $37 000 per life-year gained or $60 000 per QALY gained in the overall NLST cohort.
When examined across risk strata, incremental costs for LDCT increased with rising baseline lung cancer mortality risk (Appendix Figure 3 , available at Annals.org). Among patients with the lowest lung cancer mortality risk, the incremental cost of LDCT largely reflected the difference in screening costs ($254 for LDCT and $42 for radiography). In contrast, besides the higher costs associated with more lung cancer diagnoses, higher-risk patients had more invasive testing after a positive screening result, generating additional costs (Appendix Table 4 , available at Annals.org). Among higher-risk patients, the greater incremental costs ($1500 for decile 10 vs. $890 for decile 1) offset the greater incremental benefits to yield similar ICERs across risk deciles. For the lowest-risk decile, the ICER was $75 000 per QALY, compared with $53 000 per QALY for the highest-risk decile ( Figure 2 ).
Because no participant generated an ICER greater than $100 000 per QALY, screening all participants with LDCT was cost-effective at this threshold. Conversely, no participant generated an ICER less than $50 000 per QALY, so LDCT screening was not costeffective for any participant at this lower threshold. At both thresholds, using either the risk-targeted approach or the NLST inclusion criteria screening strategy yielded identical decisions, with no aggregate savings (that is, the iNMB is 0).
Sensitivity Analyses
When extrapolating ongoing benefits of LDCT screening beyond year 7 (that is, continually diverging hazards, as shown in Appendix Figure 1 ), the overall ICER for LDCT decreases; LDCT becomes the preferred screening strategy at the threshold of $50 000 per QALY. A risk-stratified approach yields the same screening decision, generating no savings above the NLST inclusion criteria at both WTP thresholds ( Table  2) . Removal of background costs or disutility (utility weight, 1.0) for LDCT screening also improved the overall cost-effectiveness of LDCT (to $43 000 and $37 000 per QALY, respectively), making it the preferred screening strategy at the threshold of $50 000 per QALY. Risk stratification identified some low-risk participants for whom LDCT screening was not costeffective under these scenarios at the lower WTP threshold (22% for the former and 15% for the latter). Nevertheless, the per-patient iNMBs were relatively modest, indicating that the savings from avoiding LDCT in these low-risk patients were similar in value to the lost QALYs ( Table 2) . At the threshold of $100 000 per QALY, LDCT remained cost-effective in these scenarios. 
ORIGINAL RESEARCH Risk-Targeted Selection for Lung Cancer Screening
When assigning a utility of 0.57 after a lung cancer diagnosis, LDCT screening was more cost-effective in lowthan high-risk patients but was not cost-effective for any participant at either WTP threshold. The iNMB for risk targeting remains low for all 2-and 3-way sensitivity analyses (Appendix Table 5 , available at Annals.org).
DISCUSSION
Consistent with previous findings (5-7), we demonstrated that participants at the highest baseline risk for death from lung cancer achieved the greatest benefit in terms of LDCT-prevented lung cancer deaths in the first Figure 2 . Mortality, life expectancy, and quality-of-life benefits and ICER according to risk. 
2.4
Participants were stratified by prescreening risk for lung cancer mortality, with decile 1 representing the lowest-risk 10% of the screening cohort. ICER = incremental cost-effectiveness ratio; LDCT = low-dose computed tomography; QALY = quality-adjusted life-year. A. During the initial 7-year study period, the difference in mortality benefits (number of prevented deaths per 10 000 person-years of follow-up), life expectancy, and quality of life between participants screened with LDCT and those screened with chest radiography was calculated. Those with the greatest prescreening risk for lung cancer mortality had the greatest benefit in mortality when screened with LDCT (extreme decile ratio, 7.9); however, the gradient of benefit was attenuated when accounting for life expectancy (extreme decile ratio, 3.6) and quality of life (extreme decile ratio, 2.4). B. The ICER is calculated by the ratio of the difference in costs and the difference in incremental improvement in life-years and QALYs between LDCT and chest radiography screening. The ICER remains between $100 000 and $50 000 per QALY for all risk deciles.
Risk-Targeted Selection for Lung Cancer Screening ORIGINAL RESEARCH 7 years after screening initiation: 80% of lives can be saved by targeting the highest-risk 60%. However, higher-risk participants were older, had greater smoking exposure, and were more likely to have a preexisting diagnosis of chronic obstructive pulmonary disease; the gradient of benefit across risk strata was greatly attenuated when expressed as life-years and QALYs over a lifetime time horizon. Participants at greater risk for lung cancer also generated higher lung cancer screening costs because they had more invasive testing after a positive result. Thus, the costeffectiveness of screening lower-risk patients meeting NLST criteria was similar to that of screening higher-risk participants. An individualized risk-targeted approach to participant selection for screening proved no more cost-effective than the broader NLST inclusion criteria at common WTP thresholds of $50 000 and $100 000 per quality-adjusted life-year (QALY) gained.
When our model assumptions were tested, in most scenarios, the cost-effectiveness of NLST-based screening and individualized (risk-based) screening strategies yielded the same decisions: screen everyone with either LDCT or chest radiography, depending on the WTP threshold. Even in sensitivity analyses in which LDCT screening was cost-effective for some high-risk participants and not for low-risk participants, individualizing decisions did not yield substantial benefits, because the tradeoffs involved exchanging costs and QALYs that were nearly equivalent in value. Under the sensitivity analysis applying lower utility weights after a lung cancer diagnosis reduced the health benefits of cancer detection, screening was actually less costeffective in high-versus low-risk participants.
In developing their screening recommendations, both the USPSTF (2) and the American Cancer Society (3) largely adopted the NLST inclusion criteria to determine screening eligibility. Several investigators performing analyses using various prescreening riskprediction models have argued that individual riskbased selection of participants would substantially improve efficiency compared with the broader screening approach applying the NLST or USPSTF criteria (5-8).
Katki and colleagues (6) demonstrated that applying a risk-prediction model similar to the one examined in our study to preferentially screen the highest-risk participants might lead to a 20% increase in the number of lung cancer deaths prevented over 5 years, without an increase in the number of patients screened. These authors assumed that the short-term benefits regarding LDCT-prevented lung cancer deaths translate into long-term survival benefits. However, our analysis demonstrates that each older, higher-risk person with more comorbid conditions who survives lung cancer because of screening accrues fewer additional life-years than each younger, healthier, lower-risk survivor. In addition, because a lung cancer diagnosis has a substantial effect on quality of life among survivors, the absolute magnitude of the benefit gradient between higher-and lower-risk participants is smaller when expressed as QALYs. Our analysis did not account for reductions in quality of life due to the greater burden of non-lung cancer disease (such as chronic obstructive pulmonary disease and nonpulmonary tobacco-related comorbid conditions) in higher-risk participants; if these were included, we would anticipate further attenuation of the gradient of benefit of screening high-versus low-risk participants.
Although the overall ICER estimate of $60 000 per QALY from our study is lower than the $81 000 per QALY seen in an earlier economic analysis by Black and colleagues (19) , those researchers compared LDCT with no screening. When their estimates are adjusted for the incremental cost of screening with chest radiography, their ICERs are almost identical to ours. When they attempted to apply a validated lung cancer risk model (5) to their trial-based empirical economic evaluation, their results were too unstable to produce reliable costeffectiveness estimates in the risk strata because of the low and imprecisely estimated mortality rates in 5 risk subgroups and 2 treatment groups. Our multistate model was designed to address this instability (20, 21) .
Currently, implementation of lung cancer screening requires a clinician to identify a high-risk smoker and to counsel the patient on the harms and benefits of screening as well as on smoking cessation to maximize screening benefits (22). Implementation has been shown to be limited (23) , and concerns have been raised that using risk models to determine screening eligibility may further complicate and impede it (24, 25). Our analysis suggests that the gains from such risk- 
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based eligibility likely would be small when extrapolated over the longer term, assuming perfect implementation of the 2 competing strategies. Proposed as a general approach to examine heterogeneity of effects for better treatment targeting (26, 27) , risk stratification has been demonstrated to increase the absolute risk difference of the primary outcome in many trials across many conditions (higher-risk patients generally obtain more absolute benefit) (5, 6, 28 -30) . Our analysis provides a caution that this strategy may have limitations when benefits beyond the primary outcome of the study are evaluated, especially across a lifetime time horizon (31). When risk factors for the primary outcome (in this case, lung cancer mortality) have congruent effects on mortality from other causes, the gradient of benefit seen across risk groups is likely to be attenuated. Risk modeling provides an important strategy for examining heterogeneity of treatment effects to optimize treatment decisions (28) . Our analysis suggests that this approach will not always improve cost-effectiveness substantially, even when absolute treatment benefits seem to be heterogeneous within the trial; therefore, the specifics of each analysis will matter greatly.
Our findings regarding the similar costeffectiveness of screening high-and low-risk NLST participants depend on certain model assumptions. Our model relies on the conventional assumption of a constant relative effect across risk groups. Although this approach seems to be empirically justified (5), we acknowledge that the NLST was underpowered to precisely estimate screening effectiveness in every subgroup, particularly those at low risk. Although our prediction model has not been validated externally, any decrease in model performance will probably further attenuate the gradient between the highest-and lowest-risk participants, further degrading the usefulness of risk targeting. In addition, our model did not account for different tumor types, grades, and stages. Although empirical evidence shows that the effectiveness (in terms of relative risk reduction of lung cancer mortality) seems not to differ among risk strata (5), and we estimated risk-specific costs, we could not account for risk-correlated differences in tumor type, grade, and stage that might differentially affect quality of life for the lung cancer diagnosis. We also did not account for the effect of non-cancer-related illness on utility weights, which would make high-risk patients relatively less favorable to screen than low-risk patients. Nevertheless, aside from quality-of-life estimates, our model rigorously incorporated the relevant differences between higher-and lower-risk participants for each aspect of the analysis (that is, short-term benefits, life expectancy, and costs). The importance of congruent levels of granularity for these analyses recently was emphasized (31).
Our overall estimate of cost-effectiveness also is limited. Our findings are based on data from the NLST, which compared LDCT with chest radiography. The PLCO (Prostate, Lung, Colorectal, and Ovarian) cancer screening trial previously demonstrated that chest radiography as a screening method does not effectively reduce lung cancer mortality (32). Hence, our ICERs may be more favorable than they otherwise would have been if we had compared LDCT with no screening. Second, our ICER estimates do not extrapolate outside the NLST population and reflect the NLST screening protocol, which calls for 3 annual screens, whereas the current USPSTF recommendations broaden the inclusion criteria in terms of age and duration of annual screening (2) . Finally, our estimates do not reflect quality-oflife gains from the diagnosis and treatment of incidental findings, such as emphysema and coronary artery calcification, the true costs and benefits of which have not been determined. Despite enrollment in the NLST starting in 2002, we believe that the findings continue to be generalizable, particularly given the strength of the exposure-response relationship between the heavy tobacco use required for enrollment and both lung cancer and cardiopulmonary mortality (33).
We confirmed previous work showing that more early lung cancer deaths can be averted per patient screened by applying risk targeting that is more granular than the overall inclusion criteria of the NLST. However, higher-risk patients are more costly to screen and have a lower life expectancy if they survive lung cancer. Thus, applying such a risk model is unlikely to lead to substantial improvement in the cost-effectiveness of LDCT screening in terms of QALYs gained per unit cost.
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AD LIBITUM
Ezekiel
First year preclinical we were learning about bones and I loved them because they heal, as so few things ever heal. In lecture hall, I would tell my friends about my newfound love of broken bones, how they are not like the other wounds that scar, like hormone levels that overcorrect, cancers that come back. Bones get broken and reform stronger. Split edges realign and a new matrix is laid down, a building self-sufficient in its own scaffolding.
And for a few days my obsession lasted, until a Friday afternoon lecture on osteoporosis, a professor we'd never seen before walked in and handed me a plaster cast of a vertebral column and said press it between your hands. At first nothing happened, maybe this was an object lesson in the strength of our bones, but as I pressed further of course it shattered, not a long bone with a clean break but a matrix demolished, in shards and dust on my loose leaf paper notes.
I saved a couple of pieces, they stayed at the bottom of my jacket pocket like plaster shark teeth, the sharp feeling in my fingers whenever I get too comfortable an unsettling reminder at least for the rest of the evening that we are exactly as fragile as we seem.
We elected to use a multistate model for several reasons. First, the multistate model is used as a risk model (to identify the patients at high risk for lung cancer mortality) as well as to project transitions across health states to model cost-effectiveness. Unlike other regression techniques, a multistate model estimates the effects of baseline variables across several transitions simultaneously and thus addresses the semicompeting risks for the diagnosis of lung cancer and death after the lung cancer diagnosis (11) . Important for this application, this approach also jointly captures both the benefits and harms of LDCT screening, including the risks for overdiagnsosis, because patients in the LDCT group would be expected to transition more quickly to lung cancer diagnosis but more slowly from lung cancer diagnosis to lung cancer mortality. Second, unlike Markov modeling, the multistate model uses a continuous-time framework, thus making it possible to model transitions by using individual patient-level data rather than a priori transition probabilities for discrete time cycles (20) . Third, in addition to predicting the lung cancer mortality estimates that we used for stratification, the multistate model characterizes the probability distribution for each patient over all model health states at each time point, thus facilitating individualized cost-effectiveness analyses (20, 21) . Finally, because outcome rates in the NLST within each risk strata are low, use of the multistate model-predicted probabilities improves the stability of mortality estimates, overcoming the unstable cost-effectiveness estimates based on empirical data (19) . The transition from healthy smoker to cancer did not satisfy the proportional hazard assumptions. To model this transition, the observed cumulative hazard by LDCT and chest radiography was used up to year 7 after randomization. A Weibull extrapolation, stratified by LDCT and chest radiography, was used beyond year 7 after randomization. When the cumulative hazard of a diagnosis of lung cancer by chest radiography exceeded that of LDCT, a Weibull extrapolation based on screening with chest radiography alone was used. Healthy to other death (transition 2): The transition from healthy smoker to death from non-lung cancer-related causes was modeled by using the observed cumulative hazard up to year 7 after randomization, including a proportional CT-versus-radiography effect. A Weibull extrapolation, with a doubled shape parameter, based on the cumulative hazard of death from non-lung cancer-related causes among patients screened with chest radiography was used beyond year 7 after randomization. Cancer to other death (transition 3): The transition from lung cancer to death from non-lung cancer-related causes was modeled by using the observed cumulative hazard up to year 7 after randomization, including a proportional CT-versusradiography effect. A Weibull extrapolation based on the cumulative hazard of death from non-lung cancer-related causes among patients screened with chest radiography alone was used beyond year 7 after randomization. Cancer to cancer death (transition 4): The transition from lung cancer to death from lung cancer was modeled by using the observed cumulative hazard up to year 7 after randomization, including a proportional CT-versus-radiography effect. A Weibull extrapolation based on the cumulative hazard of death from lung cancer-related causes among patients screened with chest radiography alone was used beyond year 7 after randomization. Bottom. Sensitivity analysis for transition 4. Our base case assumes that the lung cancer mortality benefits seen with LDCT screening are present only during the median follow-up of the trial, that is, 7 years. The hazard ratio of death from lung cancer in the subsequent Weibull extrapolation is the same as that in patients screened with chest radiography. Our sensitivity analysis tested this assumption by extrapolating ongoing improved survival of screening with LDCT past year 7. Participants were stratified by their prescreening risk for death from lung cancer (quintile 1, low risk; quintile 5, high risk). The predicted and observed proportion of patients in each multistate transition in a given year was calculated for each patient. LDCT = low-dose computed tomography. A. Calibration plot of predicted and observed outcomes in patients screened with chest radiography. B. Calibration plot of observed and predicted outcomes for patients screened with LDCT. C. Overall c-statistic for each transition in the multistate model. Transition 1 was stratified by screening assignment. The prediction model was well-calibrated, and good internal validity was seen between the observed and predicted transition probabilities. The circled numbers correspond to the years from randomization.
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